Description:

CALGB-40502 OPEN Registration Worksheet Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=83D2C45E-345D-C493-E040-BB89AD4375BE

Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=83D2C45E-345D-C493-E040-BB89AD4375BE
Keywords:
  1. 8/27/12 8/27/12 -
  2. 1/9/15 1/9/15 - Martin Dugas
Uploaded on:

January 9, 2015

DOI:
To request one please log in.
License :
Creative Commons BY-NC 3.0 Legacy
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Breast Cancer NCT00785291 Registration - CALGB-40502 OPEN Registration Worksheet - 3057089v1.0

Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound NAB-Paclitaxel or Ixabepilone Combined With Bevacizumab as First-Line Therapy For Locally Recurrent or Metastatic Breast Cancer

Protocol Administration
Patient Demographics/pre-treatment Characteristics2
Stage
Certification Of Eligibility
In the opinion of the investigator, is the patient eligible
Certification Of Eligibility And Protocol Design
Prior Taxane as Adjuvant therapy or Neoadjuvant therapy
Receptor Status (ER/PgR)
Assigned Treatment Arm
Companion Study Calgb - 150714
Patient's initial consent given for specimen use (150714 If a patient answers "yes" to "My specimens may be used for the research described above." question #1 in the model consent, they have consented to participate in the substudy described in Appendix I. The patient should be registered to CALGB - 150714)
In the opinion of the investigator, is the patient eligible
Companion Study Calgb - 60704
Patient's initial consent given for specimen use for genetic research relating to the study treatment (60704 If a patient answers "yes" to "My blood specimen may be used for the genetic research described above." question #2 in the model consent, they have consented to participate in the substudy described in Appendix II.)
In the opinion of the investigator, is the patient eligible
Initial Patient Consent For Specimen Use
Patient's Initial Consent given for specimen kept for future use in research to learn about, prevent, or treat cancer (model consent question #3)
Patient's initial consent given for specimen(s) may be kept for use in research to learn about, prevent, or treat other health problems (for example: diabetes, Alzheimer's disease, or heart disease) (model consent question #4)
Someone may contact me in the future to ask me to take part in more research. (model consent question #5)
Companion Study Calgb - 70501
Did the patient consent to participate in 70501 (approved CALGB institutions only If yes, register the patient to 70501 during registration to CALGB 40502)

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial